TREATMENT OF ADVANCED PARKINSON'S DISEASE IN THE UNITED STATES- A COST-UTILITY MODEL

Author(s)

Tarrants ML1, Groenendaal H2, Armand C31Teva Neuroscience, Kansas City, MO, USA, 2Vose Consulting, Boulder, CO, USA, 3H. Lundbeck A/S, Paris, France

OBJECTIVES: To assess the cost-utility of rasagiline or entacapone (COMT) as adjunctive therapies to levodopa (LD) versus carbidopa/levodopa/entacapone (LCE) versus standard LD monotherapy in patients with advanced PD and motor fluctuations in the US. As PD progresses, patients and their families experience substantial health and economic burdens. Because motor fluctuations are linked to poor quality of life and higher health care costs minimizing off-time is an effective strategy for reducing costs associated with PD. METHODS: A two-year Markov model was utilized to examine the cost-effectiveness of advanced PD treatments. Patients may transition therapy every four months. Transition probabilities were obtained from clinical trial data. Medical costs, drug costs and utility weights were from published literature. RESULTS: Over two years, all therapy options showed greater effectiveness than LD alone. Rasagiline and LCE were cost saving from a payer perspective; while COMT was cost saving from a societal perspective.  Benefits over 2 years were 0.12 additional QALYs for rasagiline, COMT and LCE and 5.08 additional months with < 25% off-time for rasagiline and 4.85 for COMT and LCE versus LD alone.   CONCLUSIONS: From a payer perspective, rasagiline and LCE were dominant therapies to LD monotherapy; while COMT was effective at higher cost.  With no additional cost over a 2 year period, rasagiline presents a valuable alternative to COMT, LCE and LD monotherapy in the treatment of advanced PD patients.  Results from this cost-utility model and prior adjunctive clinical data provides ongoing support for rasagiline’s adjunctive use in moderate to advanced PD patients with motor fluctuations.

Conference/Value in Health Info

2009-10, ISPOR Europe 2009, Paris, France

Value in Health, Vol. 12, No. 7 (October 2009)

Code

PND24

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Neurological Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×